Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated

A class action lawsuit was filed against Corcept Therapeutics ($CORT) on February 20, 2026. Plaintiffs -shareholders- in the federal securities cla...

Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims

There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Ottobock SE & Co. KGaA (OBCKF) and Corcept Therapeutics (COR...

Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT) told investors approval was on track through December 2025. Then the company disclosed that the FDA had issued a Comple...

Corcept Faces Investor Suit Over Relacorilant NDA Disclosure 

The latest update is out from Corcept Therapeutics ( ($CORT) ). On March 25, 2026, Corcept Therapeutics announced U.S. FDA approval of Lifyorli (re...

Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy

Shares in biopharma company Corcept Therapeutics ($CORT) climbed as high as 48% to $48.35 following U.S. approval of Lifyorli for treating certain ...

Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?

Analysts have been eager to weigh in on the NA sector with new ratings on Corcept Therapeutics (CORT) and Fiserv (FISV). Corcept Therapeutics (CORT...

Analysts’ Opinions Are Mixed on These NA Stocks: Corcept Therapeutics (CORT) and Fiserv (FISV)

Corcept Therapeutics ($CORT) told investors relacorilant was a promising next-generation treatment for hypercortisolism supported by clinical data ...

Current Quarter	$-0.3	Next Quarter	$-0.05
Current Year	$0.23	Next Year	$1.46
QoQ Growth	+83.3%	YoY Growth	+534.8%
3Y EPS CAGR	+11.7%	Target Price	$67.40
Consensus	Buy	Upside	+60.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CORT	$41.88	+0.46%	929.59K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CORT	$41.88	+0.5%	929.59K
3
4
5
6

CORT

CORT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Corcept Therapeutics Incorporated Data in Excel

Get Corcept Therapeutics Incorporated Data in Excel